-
PPMD Joins Collaborative Research Effort to Decode How Human Muscle Regenerates
PPMD is proud to partner with the Muscular Dystrophy Association (MDA), the FSHD Society, and
-
Making the Impossible Possible: One Man’s Journey on the Camino de Santiago de Compostela
Kurt Aguilar and his wife, Cathryn Domrose, in Vigo, Spain, before starting on the Camino
-
Advocates say 2026 will be ‘an exciting time’ for DMD community
For people with Duchenne muscular dystrophy (DMD), 2026 promises to be a year of tremendous
-
Sarepta reports positive 3-year data from the EMBARK trial: 4-7 year olds treated with their microdystrophin gene therapy, Elevidys, have significantly slower disease progression
Sarepta Therapeutics announced positive topline data from the EMBARK trial, showing that Elevidys, 3 years
-
Sarepta Shares Topline Three-Year EMBARK Data for ELEVIDYS in Ambulatory Duchenne Patients
Sarepta Therapeutics, Inc. has announced positive topline three-year functional results from Part 1-treated patients in
-
A caregiver’s birthday offers an opportunity to practice self-care
January doesn’t just bring a new calendar year. For four of us in this family,
-
What’s Ahead for Your 2026 National Ambassador
For over 70 years, MDA’s National Ambassadors have been an intrinsic part of championing for
-
Solid Biosciences Shares Update on INSPIRE DUCHENNE Trial Evaluating SGT-003
Solid Biosciences, Inc., has shared updates on the company’s gene therapy program for the treatment
-
Avidity Biosciences Managed Access Program (MAP) – Frequently Asked Questions
Avidity Biosciences has released answers to frequently asked questions about their Managed Access Program (MAP)
-
New ‘pothole-filling’ RNA strategy targets the genetic root of DM1
Using a “pothole-filling” strategy that combines the precision of DNA-like strands with the versatility of
